Ischaemic and viability testing for guiding PCI are overrated: pros and cons.
作者信息
McEntegart Margaret B, Oksnes Anja, Carrillo Xavier, Delgado Victoria
机构信息
Columbia University Irving Medical Center, New York, NY, USA.
Haukeland University Hospital, Bergen, Norway.
出版信息
EuroIntervention. 2024 Mar 18;20(6):e341-e343. doi: 10.4244/EIJ-E-24-00005.
Abstract
摘要
相似文献
1
Ischaemic and viability testing for guiding PCI are overrated: pros and cons.用于指导经皮冠状动脉介入治疗（PCI）的缺血和存活心肌检测被高估了：利弊分析
EuroIntervention. 2024 Mar 18;20(6):e341-e343. doi: 10.4244/EIJ-E-24-00005.
2
Cardiac magnetic resonance for ischaemia and viability detection. Guiding patient selection to revascularization in coronary chronic total occlusions: The CARISMA_CTO study design.心脏磁共振缺血和存活检测。指导慢性完全闭塞冠状动脉血运重建患者选择：CARISMA_CTO 研究设计。
Int J Cardiol. 2018 Dec 1;272:356-362. doi: 10.1016/j.ijcard.2018.08.061. Epub 2018 Aug 22.
3
Angiography-guided Multivessel Percutaneous Coronary Intervention Versus Ischemia-guided Percutaneous Coronary Intervention Versus Medical Therapy in the Management of Significant Disease in Non-Infarct-related Arteries in ST-Elevation Myocardial Infarction Patients With Multivessel Coronary Disease.在多支冠状动脉疾病的ST段抬高型心肌梗死患者中，非梗死相关动脉严重病变管理中血管造影引导下多支血管经皮冠状动脉介入治疗与缺血引导下经皮冠状动脉介入治疗及药物治疗的比较
Crit Pathw Cardiol. 2018 Jun;17(2):77-82. doi: 10.1097/HPC.0000000000000144.
4
Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival.严重缺血性心肌病中冠状动脉搭桥术与经皮冠状动脉介入治疗的比较：长期生存率
Eur Heart J. 2025 Jan 3;46(1):72-80. doi: 10.1093/eurheartj/ehae672.
5
Preemptive percutaneous coronary intervention for coronary artery disease: identification of the appropriate high-risk lesion.择期经皮冠状动脉介入治疗冠心病：识别合适的高危病变。
Curr Opin Cardiol. 2020 Nov;35(6):712-719. doi: 10.1097/HCO.0000000000000789.
6
Effect of random deferral of percutaneous coronary intervention in patients with diabetes and stable ischaemic heart disease.随机推迟经皮冠状动脉介入治疗对糖尿病合并稳定型缺血性心脏病患者的影响。
Heart. 2020 Nov;106(21):1651-1657. doi: 10.1136/heartjnl-2019-316432. Epub 2020 Jul 21.
7
Complete percutaneous revascularisation feasibility in ischaemic heart failure is related to improved outcomes: insights from the COMMIT-HF registry.缺血性心力衰竭患者完全经皮血管重建的可行性与改善预后相关：COMMIT-HF注册研究的见解
Kardiol Pol. 2017;75(5):453-461. doi: 10.5603/KP.a2017.0018. Epub 2017 Feb 2.
8
Long-Term Outcomes of Stroke or Transient Ischemic Attack after Non-Emergency Percutaneous Coronary Intervention.非紧急经皮冠状动脉介入治疗后的卒中或短暂性脑缺血发作的长期结局。
J Stroke Cerebrovasc Dis. 2021 Jul;30(7):105786. doi: 10.1016/j.jstrokecerebrovasdis.2021.105786. Epub 2021 Apr 14.
9
Trends and Real-World Safety of Patients Undergoing Percutaneous Coronary Intervention for Symptomatic Stable Ischaemic Heart Disease in Australia.澳大利亚症状性稳定型缺血性心脏病行经皮冠状动脉介入治疗患者的趋势和真实世界安全性。
Heart Lung Circ. 2022 Dec;31(12):1619-1629. doi: 10.1016/j.hlc.2022.08.019. Epub 2022 Oct 28.
10
Mortality in Medicare patients undergoing elective percutaneous coronary intervention with or without antecedent stress testing.接受选择性经皮冠状动脉介入治疗且有或无前瞻性负荷试验的医疗保险患者的死亡率。
Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):309-14. doi: 10.1161/CIRCOUTCOMES.113.000138. Epub 2013 May 14.
本文引用的文献
1
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial.缺血性心室功能障碍患者血运重建或药物治疗的存活率和结局：REVIVED-BCIS2 试验的预先设定的二次分析。
JAMA Cardiol. 2023 Dec 1;8(12):1154-1161. doi: 10.1001/jamacardio.2023.3803.
2
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.缺血性左心室功能障碍的经皮血管重建术。
N Engl J Med. 2022 Oct 13;387(15):1351-1360. doi: 10.1056/NEJMoa2206606. Epub 2022 Aug 27.
3
Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity.基于冠状动脉疾病和缺血严重程度的 ISCHEMIA 试验结果。
Circulation. 2021 Sep 28;144(13):1024-1038. doi: 10.1161/CIRCULATIONAHA.120.049755. Epub 2021 Sep 9.
4
Association of Inducible Myocardial Ischemia With Long-Term Mortality and Benefit From Coronary Artery Bypass Graft Surgery in Ischemic Cardiomyopathy: Ten-Year Follow-Up of the STICH Trial.缺血性心肌病中诱导性心肌缺血与长期死亡率及冠状动脉搭桥手术获益的关联：STICH试验的十年随访
Circulation. 2021 Jan 12;143(2):205-207. doi: 10.1161/CIRCULATIONAHA.120.050734. Epub 2021 Jan 11.
5
Initial Invasive or Conservative Strategy for Stable Coronary Disease.稳定型冠心病的初始侵入性或保守治疗策略。
N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30.
6
Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Stress Echocardiography-Stratified Analysis of ORBITA.多巴酚丁胺负荷超声心动图缺血作为预测稳定型冠状动脉疾病经皮冠状动脉介入治疗安慰剂对照疗效的指标：ORBITA 的负荷超声心动图分层分析。
Circulation. 2019 Dec 10;140(24):1971-1980. doi: 10.1161/CIRCULATIONAHA.119.042918. Epub 2019 Nov 11.
7
Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy.心肌活力与缺血性心肌病的长期预后
N Engl J Med. 2019 Aug 22;381(8):739-748. doi: 10.1056/NEJMoa1807365.
8
The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability.无创性检查在稳定型心绞痛患者中用于明确或排除有意义的冠状动脉狭窄的表现：侧重于检测后疾病概率的荟萃分析。
Eur Heart J. 2018 Sep 14;39(35):3322-3330. doi: 10.1093/eurheartj/ehy267.
9
Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure.心肌存活性是缺血性心力衰竭诊断和治疗方法的重要组成部分。
J Nucl Cardiol. 2015 Apr;22(2):229-45. doi: 10.1007/s12350-015-0096-5. Epub 2015 Mar 3.
10
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention.基线应激心肌灌注成像结果及稳定性缺血性心脏病患者的预后随机分为最佳药物治疗联合或不联合经皮冠状动脉介入治疗。
Am Heart J. 2012 Aug;164(2):243-50. doi: 10.1016/j.ahj.2012.05.018.
Zotero 插件